Board of Directors
- Thomas J. Schall, Ph.D., President and CEO, ChemoCentryx, Inc.
- Roger Lucas, Ph.D., Vice Chairman, Techne Corporation
- Geoffrey M. Parker, Chief Business Officer, InteKrin Therapeutics, Inc.
- Edward E. Penhoet, Ph.D., Director of Alta Partners
- Samuel P. Wertheimer, Ph.D., OrbiMed Advisors, LLC
Thomas J. Schall, Ph.D.
President and CEO
One of the earliest investigators in the field of chemokine biology, Dr. Schall founded ChemoCentryx in 1997 to focus on the discovery and development of chemokine-based therapeutics. Prior to founding ChemoCentryx, Dr. Schall spent several years at a division of Schering Plough, the DNAX Research Institute, where he made fundamental contributions to the understanding of chemokines and their receptors in human disease. Before that Dr. Schall served for some years as a scientist with Genentech, Inc. During his scientific career, Dr. Schall published over 100 book chapters and articles in noted peer-reviewed journals. In his business capacity, Dr. Schall has led ChemoCentryx through several rounds of major equity investment and business development funding (>$250 million in total from all sources), in addition to raising significant amounts of non-dilutive funding (in excess of $24 million) through such sources as DARPA and the NIH / NIAID. He has overseen the company's development of a wide pipeline of drug candidates in clinical trials and preclinical development. Dr. Schall received his Ph.D. in Cancer Biology at Stanford University.
^ Return to Top
Roger Lucas, Ph.D.
Vice Chairman, Techne Corporation
Dr. Lucas is a Director of Techne Corporation, a Series A investor in ChemoCentryx. A founding member of the staff at R&D Systems, now a division of Techne, Dr. Lucas guided that company's marked growth over 10 years, where he was a principal architect of R&D Systems' innovative deal making and acquisition of key competitors.
Techne Corporation, through its two R&D Systems subsidiaries, is the world's largest manufacturer and supplier of immunoregulatory molecules to the biomedical research community.
Dr. Lucas also sits on the Board of St. Croix Medical, Discovery Genomics, Zelo Technologies, Printware and Visual Circuits.
^ Return to Top
Geoffrey M. Parker
Chief Business Officer, InteKrin Therapeutics, Inc.
Mr. Parker is Chief Business Officer of InteKrin Therapeutics, Inc. and previously served as Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. He initially joined Goldman Sachs in 1986 in the Corporate Finance department in New York. From 1997 to 2009, he led Goldman Sachs' West Region Healthcare Investment Banking practice during which time he advised many of the biotechnology industry's leading companies such as Genentech, Amgen, Gilead and Amylin. His advisory work ranged from capital market activities to strategic mergers and acquisitions. Mr. Parker earned a bachelor's degree in economics and engineering science at Dartmouth College and an MBA at the Stanford Graduate School of Business.
^ Return to Top
Edward E. Penhoet, Ph.D.
Director of Alta Partners
Edward E. Penhoet, Ph.D., has served as a member of the Corporation's Board of Directors since December 2007. Since August 2000, Dr. Penhoet has served as a director of Alta Partners, a venture capital firm. Dr. Penhoet is currently a member of the President's Council of Advisors for Science and Technology (PCAST). Dr. Penhoet currently is a member of the Independent Citizens Oversight Committee of the California Institute of Regenerative Medicine where he served as the Vice Chairman from 2004 until 2008. From July 1998 until July 2002, Dr. Penhoet served as the Dean of the School of Public Health and as a Professor of Public Health and of Molecular and Cellular Biology at the University of California, Berkeley. Dr. Penhoet was a co-founder of the Chiron Corporation, a biotechnology company, where he served as President, Chief Executive Officer and a director from its formation in 1981 until April 1998. From 1971 until 1981, Dr. Penhoet was a faculty member of the Biochemistry Department at the University of California, Berkeley. From 2004 until 2008, Dr. Penhoet served as President of the Gordon and Betty Moore Foundation. Dr. Penhoet is a member of the Institute of Medicine of the National Academy of Sciences and The American Academy of Arts & Sciences. Dr. Penhoet received a B.A. in Biology from Stanford University and a Ph.D. in Biochemistry from the University of Washington. Dr. Penhoet currently serves as a director of ZymoGenetics, Inc., as well as certain private companies.
^ Return to Top
Samuel P. Wertheimer, Ph.D.
OrbiMed Advisors, LLC
Dr. Wertheimer assumed a role on the ChemoCentryx Board in 2001 with the participation of OrbiMed as the lead investor in the Company's Series B financing. Dr. Wertheimer joined OrbiMed Advisors LLC in 2000 as a senior analyst covering private equity and small capitalization biotechnology companies.
Dr. Wertheimer was previously Director, Office of Industrial Liaison at the New York University School of Medicine. From 1996 to 1998, Dr. Wertheimer was a Director of Technology Assessment at Paramount Capital Investments, LLC, an investment group specializing in the biotechnology industry.
Dr. Wertheimer received a Ph.D. in Molecular Biology from New York University, an M.P.H. from Yale University and a B.A. from The Johns Hopkins University. Dr. Wertheimer serves on the boards of several privately held biotechnology companies.
^ Return to Top
|
